Cronos Group (NASDAQ: CRON) is one of 33 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it compare to its competitors? We will compare Cronos Group to related companies based on the strength of its profitability, institutional ownership, risk, analyst recommendations, dividends, valuation and earnings.
Valuation & Earnings
This table compares Cronos Group and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cronos Group||$25.64 million||$1.17 billion||7.94|
|Cronos Group Competitors||$218.50 million||-$99.79 million||0.56|
Cronos Group’s competitors have higher revenue, but lower earnings than Cronos Group. Cronos Group is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Cronos Group and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cronos Group Competitors||-163.69%||-267.59%||-46.37%|
Risk & Volatility
Cronos Group has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Comparatively, Cronos Group’s competitors have a beta of 2.56, meaning that their average stock price is 156% more volatile than the S&P 500.
This is a breakdown of current ratings and target prices for Cronos Group and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cronos Group Competitors||135||360||407||14||2.33|
Cronos Group currently has a consensus target price of $9.83, indicating a potential upside of 84.84%. As a group, “Medicinals & botanicals” companies have a potential upside of 115.87%. Given Cronos Group’s competitors higher probable upside, analysts clearly believe Cronos Group has less favorable growth aspects than its competitors.
Institutional and Insider Ownership
12.1% of Cronos Group shares are held by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 7.9% of Cronos Group shares are held by insiders. Comparatively, 25.8% of shares of all “Medicinals & botanicals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Cronos Group beats its competitors on 7 of the 13 factors compared.
About Cronos Group
Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada’s Marihuana for Medical Purposes Regulations.
The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in Toronto, Canada.